The Triple Agonist Era: Phase 3 Data on Weight Loss, Triglycerides, and Inflammatory Markers Unveiled
The metabolic research landscape is shifting rapidly. While single-target GLP-1 receptor agonists and dual GIP/GLP-1 combinations have dominated recent headlines,

